Zavegepant, sold under the brand name Zavzpret, is a medication used for the treatment of migraine. Zavegepant is a calcitonin gene-related peptide receptor antagonist. It is sprayed into the nose. It is sold by Pfizer. The most common adverse reactions include taste disorders, nausea, nasal discomfort, and vomiting. Zavegepant was approved for medical use in the United States in March 2023.
Medical uses Zavegepant is indicated for the acute treatment of migraine with or without aura in adults.
References
Further reading
External links Clinical trial number NCT04571060 for "Randomized Trial in Adult Subjects With Acute Migraines" at ClinicalTrials.gov Clinical trial number NCT03872453 for "Acute Treatment Trial in Adult Subjects With Migraines" at ClinicalTrials.gov


